Iovance Biotherapeutics is trading at $16.40, up 10.74%, after announcing positive Phase 2 registrational-cohort results for lifileucel in previously treated nonsquamous metastatic non-small cell lung cancer.
- The price compares with the October 28 close of $14.81; after-hours coverage also linked the jump to the announcement.
- The company scheduled a webcast for October 29, 2026, at 8:30 a.m. ET to discuss the results and TIL platform opportunities.